William A. Cochrane
Geen lopende functies
Profiel
William A.
Cochrane served as Chairman, President & CEO of Connaught Laboratories Ltd.
from 1978 to 1989.
He also served as Chairman of Vasogen, Inc., Resverlogix Corp., QSV Biologics Ltd., University Technologies International, Inc., Oncolytics Biotech, Inc., Medicure, Inc., XS Technologies, Inc., Sernova Corp., Nucleus Bioscience, Inc., Andrew Peller Ltd., Rhino Resources, Inc. (Canada), Fox Energy Corp., Immunovaccine Technologies, Inc., and IMV, Inc. He was also President of the University of Calgary from 1978 to 1978.
Cochrane is the Principal of the Order of Canada.
He founded W.A.
Cochrane & Associates, Inc. in 1989 and served as its President until 2017.
Cochrane holds a doctorate degree from the University of Toronto.
Eerdere bekende functies van William A. Cochrane
| Bedrijven | Functie | Einde |
|---|---|---|
Order of Canada
 Order of Canada Miscellaneous Commercial ServicesCommercial Services Order of Canada is an organization based in Ottawa, Canada. The organization is affiliated with the governor general of Canada, La gouverneure générale du. | Corporate Officer/Principal | 06-10-2017 |
| W.A. Cochrane & Associates, Inc. | President | 06-10-2017 |
| ONCOLYTICS BIOTECH INC. | Directeur/Bestuurslid | 31-12-2012 |
| IMV INC. | Directeur/Bestuurslid | 30-04-2012 |
| RESVERLOGIX CORP. | Voorzitter | 13-12-2010 |
Opleiding van William A. Cochrane
| University of Toronto | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| ONCOLYTICS BIOTECH INC. | Health Technology |
| MEDICURE INC. | Health Technology |
| RESVERLOGIX CORP. | Health Technology |
| IMV INC. | Health Technology |
| ANDREW PELLER LIMITED | Consumer Non-Durables |
| SERNOVA CORP. | Health Technology |
| Bedrijven in privébezit | 13 |
|---|---|
| W.A. Cochrane & Associates, Inc. | |
University Technologies International, Inc.
 University Technologies International, Inc. Miscellaneous Commercial ServicesCommercial Services University Technologies International, Inc. offers commercialization services. It offers programs such as 321 sales academy, startup primer, and accelerator programs. The firm’s services include CEO roundtable, venture mentoring service of Alberta, intellectual property management, and funding support. The company is headquartered in Calgary, Canada. | Commercial Services |
Order of Canada
Order of Canada Miscellaneous Commercial ServicesCommercial Services Order of Canada is an organization based in Ottawa, Canada. The organization is affiliated with the governor general of Canada, La gouverneure générale du. | Commercial Services |
Rio Partners Management, Inc.
 Rio Partners Management, Inc. Investment ManagersFinance Founded in 2006, Avrio Ventures Ltd (Avrio) is a venture capital firm founded in 2002 and headquarters in Calgary with additional offices located in Montreal and Toronto. The firm is also known as Avrio Capital. | Finance |
QSV Biologics Ltd.
 QSV Biologics Ltd. BiotechnologyHealth Technology QSV Biologics Ltd. manufactures biopharmaceutical products for pre-clinical research, phase I, II and III clinical trials materials. The private company is based in Edmonton, Canada. and has subsidiaries in Canada. | Health Technology |
| Rhino Resources, Inc. (Canada) | Finance |
| Immunovaccine Technologies, Inc. | Health Technology |
Fox Energy Corp.
 Fox Energy Corp. Oil & Gas ProductionEnergy Minerals Fox Energy Corp. engages in exploration and production of oil and gas. The company is headquartered in Calgary, Canada. | Energy Minerals |
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Nucleus Bioscience, Inc.
 Nucleus Bioscience, Inc. Financial ConglomeratesFinance Part of Sophiris Bio, Inc., Nucleus Bioscience, Inc. is a Canadian capital pool company. The company is based in Surrey, Canada. Nucleus Bioscience was acquired by Brightwave Ventures, Inc. on June 18, 2003. | Finance |
Nventa Biopharmaceuticals Corp.
 Nventa Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Nventa Biopharmaceuticals Corp. discovered, developed and commercialized stress protein-based therapeutic vaccines. The company was headquartered in Victoria, Canada. | Health Technology |
XS Technologies, Inc.
 XS Technologies, Inc. Financial ConglomeratesFinance XS Technologies, Inc. is a Canadian development stage company. | Finance |
| Connaught Laboratories Ltd. |
